Eledon Pharmaceuticals, Inc. (ELDN) intrinsic value & 10-year financials
Eledon Pharmaceuticals, Inc. (ELDN) has a Graham intrinsic value of $64.38 per share. At $2.13 on Oct 17, 2026, the stock trades 97% below that value.
- Graham intrinsic value
- $64.38
- Share price (Oct 17, 2026)
- $2.13
- Price vs Graham value
- 97% below
- Market cap
- $174.3M
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- -76.0%
- ROIC (10-yr avg)
- -390.7%
- Free cash flow (FY2025)
- —
ELDN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$45.6M | -$0.52 | — | — | -58.2% |
| FY2024 | — | -$36.2M | -$0.75 | — | — | -40.9% |
| FY2023 | — | -$40.3M | -$0.82 | — | — | -80.4% |
| FY2022 | — | -$88.0M | -$3.08 | — | — | -164.2% |
| FY2021 | — | -$34.5M | -$1.17 | — | — | -43.4% |
| FY2020 | $120.0K | -$22.8M | — | — | -15387.5% | — |
| FY2019 | $500.0K | -$16.0M | — | — | -3210.2% | -1957.3% |
| FY2018 | — | -$14.1M | — | — | — | — |
| FY2017 | — | -$13.1M | — | — | — | — |
| FY2016 | $0 | -$38.0M | — | -$36.5M | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Eledon Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Eledon Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just -40.7% ROIC.
Eledon Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Eledon Pharmaceuticals, Inc. is modeled at -76.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $64.38 per share.